Profile data is unavailable for this security.
About the company
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.
- Revenue in USD (TTM)0.00
- Net income in USD-108.30m
- Incorporated2004
- Employees118.00
- LocationKalvista Pharmaceuticals Inc55 Cambridge Pkwy Ste 901ECAMBRIDGE 02142-1234United StatesUSA
- Phone+1 (857) 999-0075
- Fax+1 (302) 531-3150
- Websitehttps://www.kalvista.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Harrow Inc | 130.19m | -24.41m | 450.17m | 315.00 | -- | 6.33 | -- | 3.46 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
Alto Neuroscience Inc | 0.00 | -32.74m | 451.11m | 63.00 | -- | -- | -- | -- | -1.28 | -1.28 | 0.00 | 1.41 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2133 | -- | -100.00 | -- | -201.62 | -- | -- | -- |
Aeon Biopharma Inc | 0.00 | -28.71m | 452.60m | 10.00 | -- | -- | 103.55 | -- | -0.7727 | -0.7727 | 0.00 | -3.28 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.5686 | -- | -- | -- | -- | 5.54 | -- | -- | -- |
OraSure Technologies, Inc. | 405.47m | 53.66m | 453.11m | 638.00 | 8.52 | 1.05 | 6.07 | 1.12 | 0.7204 | 0.7204 | 5.47 | 5.86 | 0.8748 | 3.15 | 7.31 | 635,536.10 | 11.58 | 0.7238 | 13.11 | 0.8212 | 44.25 | 46.94 | 13.23 | 1.13 | 8.57 | -- | 0.0018 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
PepGen Inc | 0.00 | -78.63m | 455.87m | 64.00 | -- | 3.10 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Inozyme Pharma Inc | 0.00 | -71.17m | 456.49m | 59.00 | -- | 3.25 | -- | -- | -1.39 | -1.39 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -41.86 | -45.00 | -45.82 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2417 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
Ocugen Inc | 0.00 | -75.53m | 456.57m | 84.00 | -- | 7.82 | -- | -- | -0.3242 | -0.3242 | 0.00 | 0.2277 | 0.00 | -- | -- | 0.00 | -79.11 | -83.81 | -91.61 | -96.15 | -- | -- | -- | -446,793.90 | -- | -- | 0.0453 | -- | -- | -- | -39.38 | -- | 74.43 | -- |
Caribou Biosciences Inc | 34.48m | -102.07m | 462.41m | 158.00 | -- | 1.23 | -- | 13.41 | -1.45 | -1.45 | 0.4675 | 4.17 | 0.0856 | -- | 17.14 | 218,208.90 | -25.33 | -- | -27.24 | -- | -- | -- | -296.05 | -- | -- | -19,343.17 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Larimar Therapeutics Inc | 0.00 | -36.95m | 463.51m | 42.00 | -- | 3.90 | -- | -- | -0.8416 | -0.8416 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -33.24 | -42.22 | -36.56 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Arbutus Biopharma Corp | 18.14m | -72.85m | 466.68m | 73.00 | -- | 4.17 | -- | 25.73 | -0.4386 | -0.4386 | 0.1093 | 0.6241 | 0.1068 | -- | 11.60 | 248,506.80 | -42.88 | -52.62 | -51.22 | -58.11 | -- | -- | -401.57 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 467.02m | 118.00 | -- | 4.32 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
Akebia Therapeutics Inc | 194.62m | -51.93m | 468.99m | 167.00 | -- | -- | -- | 2.41 | -0.2778 | -0.2778 | 1.04 | -0.1572 | 0.6512 | 2.22 | 4.89 | 1,165,407.00 | -17.37 | -37.42 | -28.19 | -56.00 | 78.76 | 69.13 | -26.68 | -82.25 | 1.03 | -7.64 | 8.46 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
iTeos Therapeutics Inc | 12.60m | -112.64m | 472.05m | 157.00 | -- | 0.8205 | -- | 37.48 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
Altimmune Inc | 279.00k | -78.47m | 477.65m | 52.00 | -- | 3.12 | -- | 1,712.01 | -1.57 | -1.57 | 0.0055 | 2.85 | 0.0014 | -- | 0.3698 | 5,365.39 | -40.05 | -41.05 | -43.09 | -44.12 | -- | -- | -28,124.01 | -1,013.75 | -- | -- | 0.00 | -- | -101.54 | -- | 12.75 | -- | -5.40 | -- |
Entrada Therapeutics Inc | 129.01m | -6.69m | 482.18m | 159.00 | -- | 1.98 | -- | 3.74 | -0.2543 | -0.2543 | 3.86 | 7.25 | 0.3578 | -- | -- | 811,402.50 | -1.85 | -- | -2.47 | -- | -- | -- | -5.18 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
Marinus Pharmaceuticals Inc | 30.99m | -141.41m | 483.59m | 165.00 | -- | 28.81 | -- | 15.61 | -2.63 | -2.63 | 0.5766 | 0.3072 | 0.144 | 1.55 | 6.11 | 187,812.10 | -65.70 | -49.64 | -77.53 | -57.76 | 93.76 | -- | -456.31 | -518.96 | 4.01 | -14.97 | 0.8132 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
Holder | Shares | % Held |
---|---|---|
Tang Capital Management LLCas of 31 Dec 2023 | 3.44m | 8.28% |
Adage Capital Management LPas of 15 Feb 2024 | 2.85m | 6.84% |
Suvretta Capital Management LLCas of 31 Dec 2023 | 2.68m | 6.46% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 2.05m | 4.94% |
Saturn V Capital Management LLCas of 31 Dec 2023 | 1.81m | 4.35% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 1.75m | 4.22% |
Jefferies Investment Advisers LLCas of 31 Dec 2023 | 1.08m | 2.60% |
Driehaus Capital Management LLCas of 31 Dec 2023 | 1.03m | 2.47% |
Citadel Advisors LLCas of 31 Dec 2023 | 783.70k | 1.89% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 716.96k | 1.73% |